top of page
  • Writer's pictureSBIJI Innovation

Adicet Bio Receives $10 Million Product Development Milestone From Regeneron

August 5, 2020

Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that it has received a $10 million milestone payment from Regeneron associated with ADI-002 meeting key preclinical development goals, in accordance with the terms of its strategic collaboration with Regeneron. ADI-002 is the first of Adicet Bio’s allogeneic off-the-shelf γδ T cell product candidates to specifically target solid tumors. ADI-002 is being developed and engineered by Adicet to express a GPC3-targeting chimeric antigen receptor and IL-15.

14 views0 comments

Recent Posts

See All


bottom of page